A Phase 1, Double-Blind, Placebo Controlled, Repeat-Dose Study of the Safety, Activity and Pharmacokinetics of HQK-1001 in Healthy Volunteers
Latest Information Update: 06 Nov 2021
Price :
$35 *
At a glance
- Drugs HQK 1001 (Primary)
- Indications Beta-thalassaemia; Sickle cell anaemia
- Focus Adverse reactions
- Sponsors HemaQuest Pharmaceuticals
- 12 May 2014 New trial record